NEW YORK, January 30, 2026, 20:18 EST — The market has closed.
Walmart (WMT) shares climbed roughly 1.5% on Friday, finishing at $119.14. The stock managed to stay strong heading into the weekend, despite a volatile finish for U.S. stocks at month-end.
Wall Street’s key indexes closed down following President Donald Trump’s nomination of Kevin Warsh to succeed Jerome Powell as Fed chair, alongside a stronger-than-expected inflation report that rattled rate expectations. “Markets are calibrating to Trump’s pick of Kevin Warsh,” said Michael Hans, chief investment officer at Citizens Wealth. Reuters
Walmart’s stock tends to behave like a defensive consumer-staples play — think companies offering everyday essentials that stay in demand even when wallets tighten. The key question: will that cushion hold if concerns about rates and inflation resurface next week?
Walmart highlighted its pharmacy efforts by promoting 3,000 pharmacy technicians to operations team lead roles. This move boosted the average hourly rate from $22 to $28. Pharmacy technicians can now earn up to $40.50 an hour, while team leads might see wages as high as $42, excluding bonuses, depending on the location.
Lisa Simon, chief economist at Revelio Labs, noted that actions like these can cut costs and ease the hiring process for certified pharmacy staff. “Paying for certification is often cheaper than competing for outside hires,” she explained. Kevin Host, Walmart’s senior vice president of pharmacy, described the move as an effort to “support the pharmacy teams” serving local communities. Fortune
The late-week action put Walmart ahead of a few retail rivals: Target climbed 2.6% on Friday, but Costco Wholesale dropped 1.2%, and Amazon edged down 1%.
Still, it’s not a one-way street. Rising wages push up operating costs, and competition is intensifying in pharmacy delivery and weight-loss drugs. On top of that, a wider slump in consumer spending could challenge Walmart’s “defensive” status.
The next major event for investors is Walmart’s fiscal 2026 fourth-quarter earnings report, set for Feb. 19 at 7:00 a.m. Central. Attention will focus on margin details and any new information about the speed of its health-and-pharmacy rollout.
